Multiple Sclerosis Disease Activity Test May Help Guide Therapies

Why It Matters

The test offers clinicians an objective, real‑time metric to adjust therapies, potentially improving outcomes and reducing reliance on frequent MRIs.

Key Takeaways

• Octave MSDA test analyzed over 26,000 samples
• Anti‑CD20 therapies showed median scores 1.9 points lower
• 94% of anti‑CD20 tests fell in low activity
• Clinicians use MSDA for baseline, monitoring, relapse assessment

Pulse Analysis

Multiple sclerosis remains a leading cause of disability, and clinicians have long grappled with the challenge of monitoring disease activity between clinic visits. Magnetic resonance imaging provides high‑resolution insight but is costly, time‑consuming, and limited by patient tolerance. In recent years, blood‑based biomarker panels have emerged as a promising adjunct, offering a less invasive snapshot of the underlying immunological landscape. The Octave MSDA test, which aggregates dozens of protein markers into a single activity score, is positioned to fill this gap by delivering actionable data in real time.

The recent poster presented at the Consortium of Multiple Sclerosis Centers Annual Meeting leveraged over 26,000 MSDA results from patients on two major therapeutic classes: natalizumab and anti‑CD20 antibodies such as ocrelizumab and rituximab. Anti‑CD20 recipients consistently recorded lower median scores—1.9 units below natalizumab—indicating reduced biomarker‑derived disease activity. Moreover, 94% of anti‑CD20 tests fell within the low‑activity bracket, compared with 64% for natalizumab. These findings underscore distinct immunological footprints of each mechanism of action and suggest the MSDA test can differentiate therapeutic impact beyond conventional clinical endpoints.

Looking ahead, integration of the MSDA test into routine practice could reshape treatment algorithms for multiple sclerosis. By providing an objective, quantifiable measure alongside MRI and neurological exams, physicians may intervene earlier during subclinical disease flares, tailor therapy switches, and better manage high‑risk periods such as pregnancy. However, broader adoption hinges on prospective validation, payer acceptance, and clear guidelines on interpreting score thresholds. As the field moves toward precision neurology, blood‑based disease activity assays like Octave’s MSDA test are poised to become a cornerstone of personalized MS care.